Tag: global eylea market

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Eylea Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The eylea market has demonstrated strong expansion over recent years. It is anticipated to increase from $9.94 billion in 2024 to $10.51 billion by 2025, registering a compound annual growth rate (CAGR) of 5.7%. This historical growth can be attributed to the prevalence of diabetic macular edema (DME), its clinical efficacy and safety profile, competition with other anti-VEGF therapies, approval for various retinal conditions, and a shift towards intravitreal injections.

The eylea market is projected to observe robust expansion in the forthcoming years. It is expected to attain a valuation of $13.64 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.7%. The anticipated growth during this period stems from factors such as emerging therapeutic indications, the introduction of biosimilar competition, increasing awareness and diagnosis, the availability of real-world evidence and post-market studies, and patient preference for less frequent injections. Significant trends during the forecast period are set to include advancements in imaging technologies, the rise of telemedicine and remote monitoring, the development of patient assistance programs, ongoing advances in drug delivery technologies, improvements in retinal imaging technologies, and clinical trials for new indications.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

Which Industry Drivers Are Expected To Accelerate The Eylea Market From 2025 To 2029?

The rising prevalence of ocular conditions is anticipated to boost the Eylea market. Ocular diseases encompass eye impairments that hinder the eye’s proper functioning and negatively impact visual acuity and clarity. These conditions frequently present without symptoms until they have reached advanced stages. Eylea is utilized to address various ocular diseases, including wet age-related macular degeneration (AMD) and glaucoma, which cause damage to the retina or macula, thereby affecting vision. Eylea works by inhibiting the protein responsible for the development of new, weaker blood vessels and alleviating retinal swelling caused by blockages in the blood vessels. For example, in October 2022, the BrightFocus Foundation, a US-based nonprofit organization dedicated to advancing research and support for macular degeneration and glaucoma, reported that 80 million individuals worldwide were living with glaucoma, a figure projected to increase to over 111 million by the year 2040. Consequently, the growing occurrence of ocular diseases is a key driver for the Eylea market.

What Are The Key Segments In The Eylea Market?

The eylea market covered in this report is segmented –

1) By Product: Prefilled Syringe Package, Vial Package

2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders

3) By Application: Hospitals, Retail Pharmacy, Other Applications

Subsegments:

1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes

2) By Vial Package: Single-Dose Vials, Multi-Dose Vials

How Are Trends Influencing The Eylea Market?

Research and development activities represent a key trend gaining traction in the eylea market. A primary focus for the leading industry participants in eylea is the creation of innovative technical solutions. For example, in August 2023, Regeneron Pharmaceuticals, Inc., a global biotechnology company based in the US specializing in medicines for serious diseases, secured US FDA approval for Eylea HD (aflibercept) injection 8 mg. This approval is intended for patients afflicted with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The treatment regimen specifies an initial period of administration every four weeks for the first three months across all indications, followed by modified intervals of every eight to 16 weeks for wAMD and DME, and every eight to 12 weeks for diabetic retinopathy.

Who Are The Prominent Global Companies Shaping The Eylea Market?

Major companies operating in the eylea market include Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., GlaxoSmithKline plc, Biogen Inc., Alcon Inc., Johnson & Johnson, Eli Lilly and Company, Genentech Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Samsung Bioepis Co. Ltd., Lupin Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Torrent Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals LLC, Apotex Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

Which Geographies Are Emerging As Strong Markets For The Eylea Industry?

North America was the largest region in the eylea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Eylea Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9155&type=smp

Browse Through More Reports Similar to the Global Eylea Market 2025, By The Business Research Company

Iot In Manufacturing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/iot-in-manufacturing-global-market-report

Power Generators Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/power-generators-global-market-report

Ventricular Assist Device Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ventricular-assist-device-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Are The Market Size Estimates For The Eylea Market?

In the past few years, the Eylea market has experienced robust growth. The market size is projected to elevate from $9.94 billion in 2024 to $10.51 billion in 2025, with a compound annual growth rate (CAGR) of 5.7%. The historic period’s growth can be credited to the prevalence of Diabetic Macular Edema (DME), the clinical effectiveness and safety profile, its competitive edge over other anti-VEGF therapies, its approval for different retinal conditions, and the trend towards intravitreal injections.

The size of the Eylea market is projected to experience substantial expansion in the coming years, swelling to $13.64 billion in 2029 with a compound annual growth rate (CAGR) of 6.7%. This predicted growth for the forecasted period can be credited to factors such as the emergence of therapeutic indications, the arrival of biosimilar competition, the growth in awareness and diagnosis, real-world data and post-market research, and patient preference for less frequent injections. Key trends noted for the forecast period encompass advancements in imaging technologies, the proliferation of telemedicine and remote monitoring, patient assistance schemes, progress in drug delivery technologies, retinal imaging technologies, and clinical trials for innovative indications.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

What Growth-Enabling Forces Are Impacting The Eylea Market?

The rise in ocular disease cases is anticipated to boost the Eylea market. Ocular diseases, which directly impact one’s vision and the eye’s ability to function correctly, typically exhibit no symptoms until they are significantly advanced. Eylea is employed to deal with conditions such as these, including glaucoma and wet age-related macular degeneration (AMD), both of which cause retinal or macular damage and hinder vision. Eylea’s function involves obstructing the protein that instigates the creation of feeble new blood vessels and reduces swelling in the retina induced by obstructed blood vessels. Notably, in October 2022, the BrightFocus Foundation reported that there were approximately 80 million global glaucoma cases, with this number projected to increase to over 111 million by 2040. Consequently, the escalating occurrence of ocular diseases is a significant factor propelling the Eylea market.

How Is The Eylea Market Segmented Across Key Categories?

The eylea market covered in this report is segmented –

1) By Product: Prefilled Syringe Package, Vial Package

2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders

3) By Application: Hospitals, Retail Pharmacy, Other Applications

Subsegments:

1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes

2) By Vial Package: Single-Dose Vials, Multi-Dose Vials

What Key Trends Are Driving Growth In The Eylea Market?

Advancements in research are becoming an increasing trend in the Eylea market. Major industry players in Eylea are prioritizing the development of innovative technical solutions. For example, Regeneron Pharmaceuticals, Inc., a biotechnology company based in the US and focused on developing medications for severe illnesses, got the green light from the US FDA in August 2023 for their Eylea HD (aflibercept) injection 8 mg. This approval will help treat patients suffering from wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The approved treatment method begins with an interval of every four weeks for the first three months across all indications, before adjusting to eight to 16-week intervals for wAMD and DME and eight to 12 weeks for diabetic retinopathy.

Who Are The Leading Companies Driving The Eylea Market?

Major companies operating in the eylea market include Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., GlaxoSmithKline plc, Biogen Inc., Alcon Inc., Johnson & Johnson, Eli Lilly and Company, Genentech Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Samsung Bioepis Co. Ltd., Lupin Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Torrent Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals LLC, Apotex Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

Which Region Dominates The Eylea Market Today?

North America was the largest region in the eylea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=9155&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Eylea Industry?

The market size of Eylea has seen significant growth in recent years. It’s expected to increase from $9.94 billion in 2024 to $10.51 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.7%. The market expansion during the previous period is credited to the increasing prevalence of diabetic macular edema (DME), competitive efficiency and safety measures, competition against other anti-VEGF therapies, the approval of several retinal conditions, and a shift towards intravitreal injections.

Strong expansion is projected for the eylea market in the coming years, with its value expected to reach “$13.64 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.7%.” Factors contributing to this predicted growth within the forecast period include new therapeutic indications, the emergence of biosimilar competition, increased awareness and diagnoses, real-world evidence, and post-market studies, coupled with a patient preference for less frequent injections. The forecast period also foresees key trends such as improvements in imaging technologies, the rise of telemedicine and remote monitoring, patient assistance schemes, progressions in drug delivery technologies, retinal imaging technologies, and clinical trials targeting new indications.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

#Which Factors Are Currently Driving The Growth Of The Eylea Market?

The anticipated surge in ocular diseases is predicted to drive the growth of the Eylea market. Ocular diseases are eye disorders which impede the accurate function of the eyes and adversely impact vision clarity. These conditions often remain symptom-free until they have significantly progressed. Eylea is adept at treating such diseases including wet age-related macular degeneration (AMD) and glaucoma, conditions that cause harm to the retina or macula and subsequently, the eyesight. Eylea’s mechanism of action involves inhibiting a protein responsible for the formation of new and weaker blood vessels while also reducing the swelling in the retina attributed to a blood vessel blockage. As reported by BrightFocus Foundation, a US-based nonprofit involved in promoting research and backing for macular degeneration and glaucoma, in October 2022, the global glaucoma patient population was 80 million, with an expected escalation to over 111 million by 2040. This rise in ocular diseases is serving as a key driver for the Eylea market.

How Is The Global Eylea Market Structured In Terms Of Segments?

The eylea market covered in this report is segmented –

1) By Product: Prefilled Syringe Package, Vial Package

2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders

3) By Application: Hospitals, Retail Pharmacy, Other Applications

Subsegments:

1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes

2) By Vial Package: Single-Dose Vials, Multi-Dose Vials

Which Trends Are Redefining The Future Landscape Of The Eylea Industry?

In the eylea market, one emerging trend is the constant research and developments by the major industry players. Their top priority is to create advanced technical solutions. An example of this is Regeneron Pharmaceuticals, Inc., a biotechnology company from the US that produces medicine for serious diseases. They obtained US FDA approval in August 2023 for their Eylea HD (aflibercept) injection 8 mg. This product has been designed to help patients suffering from wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The recommended administration for this drug begins with a period of once every four weeks for the first three months for all conditions mentioned. Subsequently, the schedule is adjusted to intervals of every eight to 16 weeks for wAMD and DME, and every eight to 12 weeks for diabetic retinopathy.

Who Are The Main Participants Shaping The Eylea Market Landscape?

Major companies operating in the eylea market include Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., GlaxoSmithKline plc, Biogen Inc., Alcon Inc., Johnson & Johnson, Eli Lilly and Company, Genentech Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Samsung Bioepis Co. Ltd., Lupin Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Torrent Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals LLC, Apotex Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

Which Region Currently Holds The Largest Share In The Eylea Market?

North America was the largest region in the eylea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9155&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Eylea Industry?

In the past few years, robust growth has been observed in the Eylea market size. The projected growth is from $9.94 billion in 2024 to an estimated $10.51 billion by 2025, representing a compound annual growth rate (CAGR) of 5.7%. Factors contributing to this progressive growth during the historic period are attributable to the widespread prevalence of diabetic macular edema (DME), the clinical effectiveness and safety profiles, competition posed by other anti-VEGF therapies, approvals for a variety of retinal conditions, and a shift towards the use of intravitreal injections.

In the approaching years, the eylea market is predicted to witness robust growth, escalating to $13.64 billion in 2029 with a compound annual growth rate (CAGR) of 6.7%. This growth during the prediction period can be ascribed to factors such as rising therapeutic indications, the arrival of biosimilar competition, enhanced awareness and diagnosis, real-world validation and post-market research, and a patient preference for less frequent injections. Key trends for the forecast period comprise advancements in imaging technologies, the rise of telemedicine and remote tracking, patient assistance plans, advancements in drug delivery innovations, retinal imaging technologies, and clinical trials for novel indications.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

#Which Factors Are Currently Driving The Growth Of The Eylea Market?

The escalating incidence of eye diseases is predicted to drive the Eylea market. Eye diseases, which impede the eye’s capacity to function correctly and adversely impact vision and eye clarity, are becoming increasingly common. These conditions often go undetected until they are significantly progressed. Eylea is used to manage eye diseases like wet age-related macular degeneration (AMD) and glaucoma, both of which damage the retina or macula, affecting sight. Eylea functions by blocking the protein that forms new, weaker blood vessels, and reducing swelling in the retina induced by blood vessel blockage. To illustrate, in October 2022, the BrightFocus Foundation, an American nonprofit organization committed to promoting research and support for macular degeneration and glaucoma, reported that there were 80 million people globally suffering from glaucoma. These numbers are expected to rise to over 111 million by 2040. Consequently, this upsurge in eye diseases is fueling the Eylea market.

How Is The Global Eylea Market Structured In Terms Of Segments?

The eylea market covered in this report is segmented –

1) By Product: Prefilled Syringe Package, Vial Package

2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders

3) By Application: Hospitals, Retail Pharmacy, Other Applications

Subsegments:

1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes

2) By Vial Package: Single-Dose Vials, Multi-Dose Vials

What Trends Are Currently Influencing Growth In The Eylea Market?

Innovations and research have emerged as pivotal trends in the eylea market. Big players in the sector are heavily investing in avant-garde technical advancements. Taking an example, in August 2023, Regeneron Pharmaceuticals, Inc., a biotechnology company stationed in the US and dedicated to medicine creation for critical diseases, won US FDA nod for Eylea HD (aflibercept) injection 8 mg. This new advancement aims to cater to patients suffering from ailments like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The routine administration includes an initial span of every four weeks for the first three months for all indications, followed by alterations to every eight to 16 weeks for wAMD and DME, and every eight to 12 weeks for diabetic retinopathy.

Who Are The Main Participants Shaping The Eylea Market Landscape?

Major companies operating in the eylea market include Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., GlaxoSmithKline plc, Biogen Inc., Alcon Inc., Johnson & Johnson, Eli Lilly and Company, Genentech Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Samsung Bioepis Co. Ltd., Lupin Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Torrent Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals LLC, Apotex Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

Which Region Currently Holds The Largest Share In The Eylea Market?

North America was the largest region in the eylea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9155&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the eylea industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What Is the Current and Projected Market Size of the Eylea Market Through 2034?

Over the past few years, the eylea market has seen consistent growth. The market size, which sits at $8.09 billion in 2024, is forecasted to rise to $8.49 billion in 2025, registering a compound annual growth rate (CAGR) of 4.9%. The driving forces behind this historical growth include the prevalence of diabetic macular edema (DME), the therapy’s proven clinical efficacy and safety, its competition with other anti-VEGF therapies, regulatory approval for a range of retinal conditions, and a shift in favour of intravitreal injections.

In the ensuing years, it is anticipated that the eylea market size will experience robust growth. The projection for 2029 is a rise to $10.75 billion, with a compound annual growth rate (CAGR) of 6.1%. Factors such as emerging therapeutic indicators, the arrival of biosimilar rivals, heightened awareness and diagnostics, substantial real-world proofs, and analysis post-market studies, and patient’s preference for less regular injections contribute to this growth during the forecast period. The period is also expected to see trends such as advancements in imaging technology, the advent of telemedicine and remote surveillance, patient aid programs, developments in medication delivery technology, retinal imaging technology, and clinical trials geared towards new indications.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Eylea Market?

The Eylea market is anticipated to be driven by the rising occurrence of ocular diseases. Such diseases impair the eyes’ functioning and can adversely impact vision clarity. Often, these conditions progress significantly before exhibiting any symptoms. Eylea offers treatment for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, both of which can damage the retina or macula and compromise vision. This product acts by inhibiting a protein responsible for forming new, weaker blood vessels, and reduces swelling in the retina induced by blocked blood vessels. In the context of this, the BrightFocus Foundation, a nonprofit organization- dedicated to promoting research for macular degeneration and glaucoma from the US, reported in October 2022 that the count of individuals suffering from glaucoma globally stood at 80 million, and projected this to surge to over 111 million by 2040. Consequently, the escalating incidence of ocular diseases is fuelling the Eylea market.

Which Key Market Segments Comprise the Eylea Market and Drive Its Revenue Growth?

The eylea market covered in this report is segmented –

1) By Product: Prefilled Syringe Package, Vial Package

2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders

3) By Application: Hospitals, Retail Pharmacy, Other Applications

Subsegments:

1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes

2) By Vial Package: Single-Dose Vials, Multi-Dose Vials

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=9155&type=smp

Which Areas Are Leading Regions in the Eylea Market Expansion Across the Globe?

North America was the largest region in the eylea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Strategic Trends Steering theEylea Market Direction?

The eylea market is seeing significant growth due to the increasing focus on research and development. Major players in the industry are showing a heightened interest in producing innovative technical solutions for eylea. For instance, in August 2023, US-based biotech company Regeneron Pharmaceuticals, Inc., known for its work on serious diseases, earned approval from the US FDA for its Eylea HD (aflibercept) injection 8 mg. This treatment is designed for patients dealing with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The administration protocol requires an early period of weekly doses for the first three months in all cases, before moving on to adjusted intervals of eight to 16 weeks for wAMD and DME cases, and eight to 12 weeks for patients with diabetic retinopathy.

View the full report here:

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

How Is the Eylea Market Conceptually Defined?

Eylea is a type of drug injected into the eye that helps slow vision loss and certain other diseases by blocking the leaking and growth of fluid from abnormal blood vessels from the back of the eye. It is used to treat age-related macular degeneration (AMD).

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9155

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Primary Drivers Are Supporting the Continued Market Growth of theEylea Market?

The Eylea market is predicted to be driven by the growing incidence of ocular diseases. Defined as eye conditions that interfere with the organ’s correct functioning and adversely affect visual acuity, ocular diseases often present no detectable symptoms until they are significantly advanced. Eylea is used to treat these conditions, including ocular diseases like wet age-related macular degeneration (AMD) and glaucoma, both of which damage the retina or macula and influence vision. The medication inhibits a protein responsible for developing new, weaker blood vessels and reduces swelling in the retina caused by blood vessel obstruction. For example, the BrightFocus Foundation, a US nonprofit organization committed to promoting research and support for macular degeneration and glaucoma, reported in October 2022 that currently 80 million people worldwide suffer from glaucoma, with this figure set to surge to over 111 million by 2040. Consequently, the escalating incidence of ocular diseases is fueling the Eylea market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

#How Does the ProjectedEylea Market Growth Compare Over the Forecast Period?

The market size of Eylea has been experiencing a consistent growth in the past few years. The market valuation is projected to escalate from $8.09 billion in 2024 to $8.49 billion in 2025, marking a compound annual growth rate (CAGR) of 4.9%. The expansion in the historical phase is due to factors such as the commonness of diabetic macular edema (DME), demonstrated efficacy and safety, competition with other anti-VEGF treatments, approval for different retinal conditions, and a shift towards intravitreal injections.

The market size for Eylea is predicted to experience robust expansion in the coming years, reaching a valuation of $10.75 billion in 2029 with a 6.1% CAGR. The growth anticipated during the forecast period can be linked to factors such as the emergence of new therapeutic indications, the advent of biosimilar competition, heightened awareness and diagnosis, real-world evidence, and post-market studies, as well as patient preferences for fewer injections. Notable trends during the forecast period encompass progress in imaging technologies, the incorporation of telemedicine and remote monitoring, patient assistance programs, advances in drug delivery technologies, developments in retinal imaging techniques, and ongoing clinical trials for novel indications.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9155

How Are Consumer Market Innovations Shaping the Current and Future Landscape of theEylea Market?

The eylea market is witnessing a growing trend in research and development, with industry leaders focusing on introducing advanced technical solutions. Take, for instance, Regeneron Pharmaceuticals, Inc., a biotechnology company from the USA that specializes in producing medications for severe diseases. In August 2023, the company obtained U.S. FDA approval for Eylea HD (aflibercept) injection 8 mg, designed to treat patients suffering from wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The injection protocol starts with a period of every four weeks in the initial three months for all mentioned conditions. This protocol then changes to intervals of every eight to 16 weeks for wAMD and DME and eight to 12 weeks for diabetic retinopathy.

Who Are the Key Market Players Influencing the Growth of the Corn and Eylea Industry?

Major companies operating in the eylea market include Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., GlaxoSmithKline plc, Biogen Inc., Alcon Inc., Johnson & Johnson, Eli Lilly and Company, Genentech Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Samsung Bioepis Co. Ltd., Lupin Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Torrent Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals LLC, Apotex Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

Which Key Market Segments Comprise the Eylea Market and Drive Its Revenue Growth?

The eylea market covered in this report is segmented –

1) By Product: Prefilled Syringe Package, Vial Package

2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders

3) By Application: Hospitals, Retail Pharmacy, Other Applications

Subsegments:

1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes

2) By Vial Package: Single-Dose Vials, Multi-Dose Vials

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=9155&type=smpGlobal Eylea Market, Global Eylea Market Report, Global Eylea Market Trends, Global Eylea Market Size

Browse Through More Reports Similar to the Gobal Eylea Maret 2025, By The Business Research Company:

Network Engineering Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/network-engineering-services-global-market-report

Product Engineering Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/product-engineering-services-global-market-report

IoT in Manufacturing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/iot-in-manufacturing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the eylea market right now?

The market size for eylea has been witnessing consistent growth over the years. This upward trend is projected to continue as the market size is expected to increase from $8.09 billion in 2024 to $8.49 billion in 2025, with a compound annual growth rate (CAGR) of 4.9%. Various factors have contributed to growth in the past, including the prevalence of diabetic macular edema (DME), the clinical effectiveness and safety profile of eylea, competition with other anti-VEGF therapies, approval for different retinal conditions, and a shift towards intravitreal injections.

How fast Is the eylea market expected to grow, and what’s its future value?

The eylea market is predicted to experience significant expansion in the forthcoming years. By 2029, it is projected to reach a value of $10.75 billion, with a compound annual growth rate (CAGR) of 6.1%. This escalation during the forecast period is ascribed to the rise of therapeutic indications, the influx of biosimilar competition, heightened awareness and diagnosis, tangible evidence and post-market research, as well as the patient’s favor towards fewer injections. Within this prediction period, the major trends to look out for are advancements in the realm of imaging technologies, the proliferation of telemedicine and remote monitoring, patient assistance programs, progress in drug delivery technologies, retinal imaging breakthroughs, and the conduction of clinical trials for new indications.

Get your eylea market report here!

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

What are the leading drivers of growth in the eylea market?

The escalating occurrence of eye disorders is anticipated to spur the growth of the Eylea market. Eye disorders, often without early symptoms, hamper the normal functioning of the eye and impair vision. Eylea is effective in treating a variety of eye disorders, including wet age-related macular degeneration (AMD) and glaucoma, which damage the retina or macula, affecting vision. Eylea functions by prohibiting a protein that forms new, vulnerable blood vessels, and reduces the swelling of the retina caused by blocked blood vessels. For example, as per the BrightFocus Foundation, a US-based nonprofit focused on promoting research and support for macular degeneration and glaucoma, in October 2022, the number of glaucoma patients worldwide stood at 80 million, with an expected surge to over 111 million by 2040. Consequently, the growing occurrence of eye diseases is bolstering the Eylea market.

What are the key segments defining the eylea market?

The eylea market covered in this report is segmented –

1) By Product: Prefilled Syringe Package, Vial Package

2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders

3) By Application: Hospitals, Retail Pharmacy, Other Applications

Subsegments:

1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes

2) By Vial Package: Single-Dose Vials, Multi-Dose Vials

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

Who are the key players steering the development of the eylea market?

Major companies operating in the eylea market include Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., GlaxoSmithKline plc, Biogen Inc., Alcon Inc., Johnson & Johnson, Eli Lilly and Company, Genentech Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Samsung Bioepis Co. Ltd., Lupin Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Torrent Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals LLC, Apotex Inc.

What emerging trends are influencing the growth of the eylea market?

The increasing popularity of research and innovation is a key trend observed in the eylea market. Major industry figures make it their main objective to develop innovative technical solutions. For example, in August 2023, Regeneron Pharmaceuticals, Inc., a global biotechnology corporation based in the United States and dedicated to creating treatments for severe diseases, secured US FDA approval for Eylea HD (aflibercept) injection 8 mg. This medication is developed to treat patients suffering from wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The administration guideline begins with a schedule of every four weeks for the initial three months for all conditions, which is then modified to every eight to 16 weeks for wAMD and DME, and every eight to 12 weeks for diabetic retinopathy.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9155

Which regions are most influential in expanding the eylea market?

North America was the largest region in the eylea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Network Engineering Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/network-engineering-services-global-market-report

Product Engineering Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/product-engineering-services-global-market-report

IoT in Manufacturing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/iot-in-manufacturing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Long-Term Projected Growth Rate for the Eylea Market, and What Are the Key Drivers?

In recent times, the Eylea market has been registering consistent growth. It is expected to increase from $8.09 billion in 2024 to $8.49 billion in 2025, which signifies a compound annual growth rate (CAGR) of 4.9%. The expansion during the previous period has been credited to factors like the prevalence of diabetic macular edema (DME), proven clinical effectiveness and good safety records, competition with other anti-VEGF treatments, approval for diverse retinal conditions, and a trend towards intravitreal injections.

The eylea market is projected to experience substantial growth in the upcoming years. It is forecasted to develop to $10.75 billion by 2029 with a compound annual growth rate (CAGR) of 6.1%. The increased growth during the forecast period can be linked to a variety of factors such as the advent of new therapeutic indications, the launch of biosimilar competitors, growing consciousness and diagnoses, real-world evidence paired with post-market research, and patients preferring less frequent injections. Mainline trends during the predicted period involve advancements in imaging technology, telemedicine, remote monitoring, patient assistance programs, progress in drug delivery technologies, retinal imaging technologies and clinical trials for new indications.

Which Major Market Drivers Are Expected to Boost the eylea Market’s Growth Potential?

The Eylea market is projected to surge due to the rising occurrence of ocular diseases. These diseases affect the eye’s capacity to function efficiently, impairing vision clarity. Often, these conditions go unnoticed until they have significantly advanced. Eylea is a treatment for ocular diseases such as wet age-related macular degeneration (AMD) and glaucoma, conditions that harm the retina or macula and impair vision. The drug works by inhibiting a protein responsible for creating new, weaker blood vessels and slowing the inflammation of the retina due to obstructed blood vessels. For example, in October 2022, the BrightFocus Foundation, a nonprofit organization in the US devoted to macular degeneration and glaucoma research and support, reported that there were 80 million people worldwide suffering from glaucoma, projected to rise to over 111 million by 2040. Hence, the escalating incidences of ocular diseases are fueling the Eylea market.

Request Your Free Eylea Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

Who Are the Major Companies Shaping the Competitive Landscape of the Eylea Market?

Major companies operating in the eylea market include:

• Regeneron Pharmaceuticals Inc._x000D_

• Bayer AG_x000D_

• Novartis AG_x000D_

• Roche Holding AG_x000D_

• Pfizer Inc._x000D_

What Are the Key Emerging Trends in the Eylea Market for the Next Decade?

The focus on research and development is a prominent trend emerging in the eylea market. The primary aim for dominant participants in the eylea sector is to create advanced technological solutions. For example, in August 2023, Regeneron Pharmaceuticals, Inc., a biotechnology firm located in the US that is engaged in producing medicine for severe diseases, obtained approval from the US FDA for Eylea HD (aflibercept) injection 8 mg. This solution is designed to treat patients suffering from wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The recommended protocol begins with an interval of every four weeks for the initial three months across all indications. This is succeeded by variable periods of every eight to 16 weeks for wAMD and DME, and every eight to 12 weeks for diabetic retinopathy.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

What Are the Major Segments of the Eylea Market and Their Role in Driving Growth?

The eylea market covered in this report is segmented –

1) By Product: Prefilled Syringe Package, Vial Package

2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders

3) By Application: Hospitals, Retail Pharmacy, Other Applications

Subsegments:

1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes

2) By Vial Package: Single-Dose Vials, Multi-Dose Vials

Which Regions Are Making a Mark in the Eylea Market Growth?

North America was the largest region in the eylea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

How Is the Eylea Market Categorized and Defined in the Industry?

Eylea is a type of drug injected into the eye that helps slow vision loss and certain other diseases by blocking the leaking and growth of fluid from abnormal blood vessels from the back of the eye. It is used to treat age-related macular degeneration (AMD).

Browse Through More Similar Reports By The Business Research Company:

Network Engineering Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/network-engineering-services-global-market-report

Product Engineering Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/product-engineering-services-global-market-report

IoT in Manufacturing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/iot-in-manufacturing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: